💊 药物 A-Z 🧬 靶点 🛠 工具 📚 指南
全部药物 药物分类 治疗领域 不良反应
指南 术语表 时间轴
药物比较 药物旅程 药物家族
🇺🇸 English 🇰🇷 한국어 🇯🇵 日本語 🇨🇳 中文简体 🇪🇸 Español 🇧🇷 Português 🇮🇳 हिन्दी 🇸🇦 العربية 🇫🇷 Français 🇷🇺 Русский 🇩🇪 Deutsch 🇹🇷 Türkçe 🇻🇳 Tiếng Việt 🇮🇩 Bahasa Indonesia 🇹🇭 ไทย

Glycopyrronium Bromide

CHEMBL1201027 Phase 4 已批准 Small molecule
Half-Life
—
Bioavailability
—
Protein Binding
—
Molecular Weight
398.3 g/mol
LogP
—
Phase
4

An anticholinergic bronchodilator used as a maintenance treatment for chronic obstructive pulmonary disease to reduce airway constriction by blocking muscarinic receptors in the lungs. The inhaled formulation provides long-acting bronchodilation to improve airflow and reduce breathlessness throughout the day. It does not provide immediate symptom relief during an acute attack.

分子量

398.3000 g/mol

TPSA

46.50 Ų

治疗领域

Bladder Cancer Pain Management Asthma Chronic Obstructive Pulmonary Disease Parkinson's Disease Generalized Anxiety Disorder Stroke Obesity Type 2 Diabetes Major Depressive Disorder Chronic Pain Heart Failure

作用机制

Activates beta-2 adrenergic receptors on bronchial smooth muscle, stimulating adenylyl cyclase and increasing intracellular cAMP. This relaxes airway smooth muscle and produces bronchodilation.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

机制

Activates beta-2 adrenergic receptors on bronchial smooth muscle, stimulating adenylyl cyclase and increasing intracellular cAMP. This relaxes airway smooth muscle and produces bronchodilation.

二维结构

SVG PNG

Cite this structure


                        

                            
                            
                        

                    

                


                
                

                    

                    

                        
Embed this structure

                        

                        

                            
                            
                        

                    

                

                

                
                

                    
SMILES

                    
C[N+]1(C)CCC(OC(=O)C(O)(c2ccccc2)C2CCCC2)C1.[Br-]

                

                

                
                

                    
InChI

                    
InChI=1S/C19H28NO3.BrH/c1-20(2)13-12-17(14-20)23-18(21)19(22,16-10-6-7-11-16)15-8-4-3-5-9-15;/h3-5,8-9,16-17,22H,6-7,10-14H2,1-2H3;1H/q+1;/p-1

                

                

                

                    
                    

                        
Molecular Formula

                        
C19H28BrNO3

                    

                    
                    

                        
HBD / HBA

                        
1 / 4

                    

                    
                    

                        
可旋转键数

                        
5

                    

                    
                    
                    

                        
重原子数

                        
24

                    

                    
                

            


            
            

                
                


    
    
        
    
    
    
No targets recorded

    
    
Target interaction data is not yet available for this drug.

    



                
            


            
            

                
                


    
    
        
    
    
    
No interactions recorded

    
    
Drug interaction data is not yet available for this compound.

    



                
            


            
            

                
                


    
    
        
    
    
    
No side effects recorded

    
    
Side effect data is not yet available for this drug.

    



                
            


            
            
            

                
常见问题

                

                    
                    

                        
                        

                            
An anticholinergic bronchodilator used as a maintenance treatment for chronic obstructive pulmonary disease to reduce airway constriction by blocking muscarinic receptors in the lungs. The inhaled formulation provides long-acting bronchodilation to improve airflow and reduce breathlessness throughout the day. It does not provide immediate symptom relief during an acute attack.

                        

                    

                    

                    

                    
                    

                        
                        

                            
Activates beta-2 adrenergic receptors on bronchial smooth muscle, stimulating adenylyl cyclase and increasing intracellular cAMP. This relaxes airway smooth muscle and produces bronchodilation.

                        

                    

                    

                    

                    

                        
                        

                            
Yes, Glycopyrronium Bromide is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

                        

                    

                

            

            

            
            

            
            

            
            
{# References & Data Sources section for drug detail pages.
   Renders standard pharmacological database links plus the drug's data_sources field. #}


    
References & Data Sources

    
    
        
        
  • 
            
            
                ChEMBL — European Bioinformatics Institute (EBI).
                CHEMBL1201027.
                Open-access bioactivity database.
            
        
    • 
        
        
        
  • 
            
            
                PubChem — National Center for Biotechnology Information (NCBI).
                CID 11693.
                Chemical information database.
            
        
    • 
        
        
        
        
    

    
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.




        


        
        
    


    



    
医疗免责声明

    

        This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.
    

    

        Data sources:
        ChEMBL,
        PubChem,
        DailyMed.